Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Atrial Fibrillation: Past, Present and Future
share announcement

Atrial Fibrillation: Past, Present and Future

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 916

Special Issue Editor

Prof. Dr. Katarzyna Mizia-Stec

E-Mail Website
Guest Editor
First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, 47 Ziołowa Str., 40-635 Katowice, Poland
Interests: atrial fibrillation; cardiology; coronary artery disease; myocardial infraction; percutaneous coronary interventions; valvular heart disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Journal of Clinical Medicine is publishing a Special Issue entitled "Atrial Fibrillation: Past, Present and Future". I am serving as the Guest Editor for this Issue.

Atrial fibrillation is a common cardiac arrhythmia characterized by irregular and often rapid heartbeats originating from the atria. It is associated with an increased risk of stroke, heart failure, and mortality. AF is a significant clinical concern due to its associated morbidity and mortality, and its prevalence is expected to increase as the population ages.

Atrial fibrillation constitutes wide range of clinical problems including atrial fibrillation prevention, diagnosis, and management.

In this Special Issue, we invite researchers to submit high-quality original papers on new insights into all these topics—the prevalence, pathophysiology, diagnosis, monitoring, risk prediction, prophylaxis, and treatment options of AF.

I think that you could make an excellent contribution based on your expertise in this field. The submission deadline is 31 March 2024. I am looking forward to hearing from you.

Kind regards,

Prof. Dr. Katarzyna Mizia-Stec
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atrial fibrillation
  • cardiac arrhythmia
  • electrocardiogram
  • rate control
  • rhythm control
  • anticoagulation therapy
  • stroke
  • heart failure
  • Holter monitoring
  • telemonitoring
  • pulmonary vein isolation
  • antiarrhythmic therapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1535 KiB  
Article
Role of CES1 and ABCB1 Genetic Polymorphisms on Functional Response to Dabigatran in Patients with Atrial Fibrillation
by Luca Cumitini, Giulia Renda, Mara Giordano, Roberta Rolla, Tarek Shail, Sara Sacchetti, Lorena Iezzi, Luca Giacomini, Valentina Zanotti, Raffaella Auciello, Ilaria Angilletta, Melissa Foglietta, Mirco Zucchelli, Ivana Antonucci, Liborio Stuppia, Sabina Gallina, Umberto Dianzani and Giuseppe Patti
J. Clin. Med. 2024, 13(9), 2545; https://doi.org/10.3390/jcm13092545 - 26 Apr 2024
Viewed by 212
Abstract
Background: Dabigatran etexilate is a pro-drug hydrolyzed into dabigatran by carboxylesterases (CES) and is a substrate of the P-Glycoprotein encoded by the adenosine-triphosphate-binding cassette sub-family B member (ABCB)1 genes. We evaluated the functional response to dabigatran according to different CES1 and ABCB1 [...] Read more.
Background: Dabigatran etexilate is a pro-drug hydrolyzed into dabigatran by carboxylesterases (CES) and is a substrate of the P-Glycoprotein encoded by the adenosine-triphosphate-binding cassette sub-family B member (ABCB)1 genes. We evaluated the functional response to dabigatran according to different CES1 and ABCB1 single-nucleotide polymorphisms (SNPs) in patients with atrial fibrillation (AF). Methods: A total of 100 consecutive patients with AF taking dabigatran were enrolled by two Italian centers. A venous blood sample was drawn for genetic determinations, as well as a measurement of the diluted thrombin time (dTT) and drug plasma concentrations, at the trough and peak. The main objective was the relationship between the dTT values and CES1 rs2244613, CES1 rs8192935 and ABCB1 rs4148738 SNP while on two different dabigatran doses (110 and 150 mg BID). Results: A total of 43 patients were on a 110 mg dabigatran dose and 57 on 150 mg. The DTT values at the trough and at peak were not different among patients with different CES1 rs2244613 and CES1 rs8192935 genotypes, regardless of the dabigatran dose. In patients on 150 mg dabigatran, the dTT values at the trough were 77 (44–111) ng/mL in patients with the ABCB1 rs4148738 heterozygous CT genotype vs. 127 (85–147) ng/mL in the wild-type CC genotype vs. 110 (47–159) ng/mL in the mutant trait TT genotype (p = 0.048). In patients with the ABCB1 rs4148738 CT genotype, OR for having dTT values at a trough below the median was 3.21, 95% CI 1.04–9.88 (p = 0.042). Conclusions: ABCB1 rs4148738 CT heterozygous is associated with the reduced anticoagulant activity of dabigatran at the trough in patients receiving the higher dose regimen. Full article
(This article belongs to the Special Issue Atrial Fibrillation: Past, Present and Future)
►▼ Show Figures

Figure 1

13 pages, 607 KiB  
Article
Principles and Limitations of miRNA Purification and Analysis in Whole Blood Collected during Ablation Procedure from Patients with Atrial Fibrillation
by Mateusz Polak, Joanna Wieczorek, Malwina Botor, Aleksandra Auguścik-Duma, Andrzej Hoffmann, Anna Wnuk-Wojnar, Katarzyna Gawron and Katarzyna Mizia-Stec
J. Clin. Med. 2024, 13(7), 1898; https://doi.org/10.3390/jcm13071898 - 25 Mar 2024
Viewed by 474
Abstract
Background: MicroRNA (miRNA) have the potential to be non-invasive and attractive biomarkers for a vast number of diseases and clinical conditions; however, a reliable analysis of miRNA expression in blood samples meets a number of methodological challenges. In this report, we presented and [...] Read more.
Background: MicroRNA (miRNA) have the potential to be non-invasive and attractive biomarkers for a vast number of diseases and clinical conditions; however, a reliable analysis of miRNA expression in blood samples meets a number of methodological challenges. In this report, we presented and discussed, specifically, the principles and limitations of miRNA purification and analysis in blood plasma samples collected from the left atrium during an ablation procedure on patients with atrial fibrillation (AF). Materials and Methods: Consecutive patients hospitalized in the First Department of Cardiology for pulmonary vein ablation were included in this study (11 with diagnosed paroxysmal AF, 14 with persistent AF, and 5 without AF hospitalized for left-sided WPW ablation—control group). Whole blood samples were collected from the left atrium after transseptal puncture during the ablation procedure of AF patients. Analysis of the set of miRNA molecules was performed in blood plasma samples using the MIHS-113ZF-12 kit and miScript microRNA PCR Array Human Cardiovascular Disease. Results: The miRNS concentrations were in the following ranges: paroxysmal AF: 7–23.1 ng/µL; persistent AF: 4.9–66.8 ng/µL; controls: 6.3–10.6 ng/µL. The low A260/280 ratio indicated the protein contamination and the low A260/A230 absorbance ratio suggested the contamination by hydrocarbons. Spectrophotometric measurements also indicated low concentration of nucleic acids (<10 ng/µL). Further steps of analysis revealed that the concentration of cDNA after the Real-Time PCR (using the PAXgene RNA Blood kit) reaction was higher (148.8 ng/µL vs. 68.4 ng/µL) and the obtained absorbance ratios (A260/A280 = 2.24 and A260/A230 = 2.23) indicated adequate RNA purity. Conclusions: Although developments in miRNA sequencing and isolation technology have improved, detection of plasma-based miRNA, low RNA content, and sequencing bias introduced during library preparation remain challenging in patients with AF. The measurement of the quantity and quality of the RNA obtained is crucial for the interpretation of an efficient RNA isolation. Full article
(This article belongs to the Special Issue Atrial Fibrillation: Past, Present and Future)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop